Delcath Systems Inc

Several biotech stocks reached 52-week highs on August 7, 2026, driven by quarterly results and clinical advancements. Delcath Systems surged over 22% to $15.62 after reporting second-quarter net revenues of $29.1 million, up from $24.2 million a year earlier, with HEPZATO product revenue growing about 30% to $27.1 million across roughly 31 active treatment centers. Alto Neuroscience rose to a 52-week high of $29.48 following last month's registered direct offering that raised an estimated $100 million to advance its lead candidate ALTO-207 toward a Phase 3 trial. Hemab Therapeutics hit $53.60 after positive Phase 2 data showed Sutacimig reduced the mean annualized treated bleeding rate by 84% in Glanzmann thrombasthenia and Factor VIII deficiency, alongside encouraging interim Phase 2 results for HMB-002 in Von Willebrand's disease. Monopar Therapeutics reached $124.31 on the back of positive Phase 3 results for ALXN1840 in Wilson disease, which earned a Rare Pediatric Disease voucher from the FDA, with an NDA submission planned by mid-2026. Nurix Therapeutics climbed to $25.49 after receiving a $10 million milestone payment from Sanofi for the Phase 1 initiation of NX-3911 and announcing with Roche the first patient enrolled in the Phase 3 DAYBreak CLL-306 trial evaluating Bexobrutideg in relapsed/refractory chronic lymphocytic leukemia.

Delcath Systems raised its full-year 2026 revenue guidance to a range of $104 million to $108 million, reflecting strong first-half performance and continued growth in HEPZATO KIT volume. Second-quarter revenue rose 20% year over year to $29.1 million, with HEPZATO KIT revenue of $27.1 million. HEPZATO volume increased 17% sequentially from the first quarter and 30% year over year. The company ended the quarter with 31 active treatment centers and remains on track to reach approximately 37 by year-end. Delcath also reported net income of $2.7 million and adjusted EBITDA of $7.6 million, while advancing Phase II trials in metastatic colorectal and HER2-negative breast cancer despite slower-than-expected enrollment.

A new report forecasts the commercial outlook for Delcath Systems' HEPZATO-KIT across the seven major markets through 2034. HEPZATO-KIT, the first FDA-approved liver-directed therapy for adults with uveal melanoma and unresectable hepatic metastases, received US approval in August 2023. The analysis covers historical performance, current utilization, and projected sales for liver metastases as well as potential indications including liver cancer and cholangiocarcinoma. Key growth drivers include the therapy's first-mover advantage, strong liver response data from the pivotal Phase III FOCUS trial showing an objective response rate of approximately 35-36% versus 12.5% for standard care, and an expanding network of authorized treatment centers. The report also examines pricing, reimbursement, competitive landscape, and lifecycle opportunities that could broaden the addressable market.